• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In
Home / References

Genelex Information References

All of the information contained on Genelex.com has been sourced from the following links or publications. If you have any questions about the information on our website, please email us at info@genelex.com.

Last updated: November 9, 2018
Citation #PageCitationLink
1Patients1. Van Driest, SL, et. al., Clin Pharmacol Ther. 2014; 95(4): 423–431. 2. Yuan, J. et. al., Jmol Diag. 2016; 18(3): 438-445https://www.ncbi.nlm.nih.gov/pubmed/24253661
2PatientsNull, G. (2011). Death by medicine. Mount Jackson, VA: Praktikos Books.
http://www.webdc.com/pdfs/deathbymedicine.pdf
3ConditionsCenter for Drug Evaluation and Research. (n.d.). Science & Research (Drugs) - Table of Pharmacogenomic Biomarkers in Drug Labeling. Retrieved from http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htmhttp://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
4CancerFlockhart, D. A. (2007). Drug interactions: cytochrome P450 drug interaction table.  Indiana University School of Medicine ,  2010 .https://drug-interactions.medicine.iu.edu/main-table.aspx
5CancerBrian Thomas Hocum, John Raymond White, Jarrod W. Heck, Ranjit K. Thirumaran, Nicolas Moyer, Richard Newman and Kristine Ashcraft American Journal of Health-System Pharmacy January 2016, 73 (2) 61-67; DOI: https://doi.org/10.2146/ajhp150273https://www.ncbi.nlm.nih.gov/pubmed/26721535
6Cancer(n.d.). Retrieved from https://www.pharmgkb.org/labelshttps://www.pharmgkb.org/labels
7DepressionAl-Harbi, K. S. (2012). Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369–388. http://doi.org/10.2147/PPA.S29716https://www.ncbi.nlm.nih.gov/pubmed/22654508
8DepressionCPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19. (n.d.). Retrieved from https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/
5DepressionBrian Thomas Hocum, John Raymond White, Jarrod W. Heck, Ranjit K. Thirumaran, Nicolas Moyer, Richard Newman and Kristine Ashcraft American Journal of Health-System Pharmacy January 2016, 73 (2) 61-67; DOI: https://doi.org/10.2146/ajhp150273https://www.ncbi.nlm.nih.gov/pubmed/26721535
9Depression(n.d.). Retrieved from https://www.pharmgkb.org/labelshttps://www.pharmgkb.org/labels
10DiabetesCDC Newsroom. (n.d.). Retrieved from https://www.cdc.gov/media/releases/2014/p0610-diabetes-report.htmlhttps://www.cdc.gov/media/releases/2014/p0610-diabetes-report.html
11DiabetesHorn, J., PharmD, & Hansten, P., PharmD. (2004). Oral Hypoglycemic Agents: The Risk of Hypoglycemia APRIL 01, 2004 John R. Horn, PharmD, FCCP, and Philip D. Hansten, PharmD. Pharmacy Times, 2004(04). Retrieved September 26, 2018.https://www.pharmacytimes.com/publications/issue/2004/2004-04/2004-04-7837
12Epilepsyhttps://www.ncbi.nlm.nih.gov/pubmed/27713373https://www.ncbi.nlm.nih.gov/pubmed/27713373
13Heart DiseaseJohnson, J. A., & Cavallari, L. H. (2013). Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine. Pharmacological Reviews, 65(3), 987–1009. http://doi.org/10.1124/pr.112.007252http://pharmrev.aspetjournals.org/content/65/3/987
14Heart DiseaseCavallari, L. H., & Weitzel, K. (2015). Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. Future Cardiology, 11(3), 281–286. http://doi.org/10.2217/fca.15.20http://doi.org/10.2217/fca.15.20
15Heart Disease(n.d.). Retrieved from https://www.pharmgkb.org/labelshttps://www.pharmgkb.org/labels
16HIVKumar S, Rao P, Earla R, Kumar A. Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert opinion on drug metabolism & toxicology. 2015;11(3):343-355. doi:10.1517/17425255.2015.996546.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428551/
17Chronic PainSchug, S., & Ting, S. (2016). The pharmacogenomics of pain management: Prospects for personalized medicine. Journal of Pain Research, 49. doi:10.2147/jpr.s55595https://www.ncbi.nlm.nih.gov/pubmed/26929662
18Chronic PainAgarwal, D., Udoji, M. A., & Trescot, A. (2017). Genetic Testing for Opioid Pain Management: A Primer. Pain and Therapy, 6(1), 93–105. http://doi.org/10.1007/s40122-017-0069-2http://doi.org/10.1007/s40122-017-0069-2
18Ulcers/Acid RefulxKlotz U, Schwab M, Treiber G. CYP2C19Polymorphism and Proton Pump Inhibitors. Basic & Clinical Pharmacology & Toxicology. 2004;95(1):2–8.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548122/
19FluorouracilDean L. Fluorouracil Therapy and DPYD Genotype. 2016 Nov 3. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395610/https://www.ncbi.nlm.nih.gov/books/NBK395610/
20PlavixSimon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., . . . Becquemont, L. (2009). Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine,360(4), 363-375. doi:10.1056/nejmoa0808227https://www.nejm.org/doi/full/10.1056/NEJMoa0808227
21TamoxifenDean L. Tamoxifen Therapy and CYP2D6 Genotype. 2014 Oct 7 [Updated 2016 May 3]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK247013/
22Stratterahttps://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021411s035lbl.pdf
23StratteraShu-Feng Zhou, Jun-Ping Liu & Balram Chowbay (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact, Drug Metabolism Reviews, 41:2, 89-295, DOI: 10.1080/03602530902843483https://www.tandfonline.com/action/showCitFormats?doi=10.1080%2F03602530902843483
24WarfarinJohnson, J. A., & Cavallari, L. H. (2015). Warfarin Pharmacogenetics. Trends in Cardiovascular Medicine, 25(1), 33–41. http://doi.org/10.1016/j.tcm.2014.09.001https://www.ncbi.nlm.nih.gov/pubmed/25282448
27WarfarinDean L. Warfarin Therapy and VKORC1 and CYP Genotype. 2012 Mar 8 [Updated 2018 Jun 11]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK84174/https://www.ncbi.nlm.nih.gov/books/NBK84174/
28WarfarinJohnson, J., Caudle, K., Gong, L., Whirl-Carrillo, M., Stein, C., Scott, S., . . . Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.  Clinical Pharmacology & Therapeutics,   102 (3), 397-404. doi:10.1002/cpt.668https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/
29CYP2C9Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting.  Mol Diagn Ther . 2013;17(3):165-84.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663206/
30CYP2C9Wise ES, Gadomski SP, McMaster WG, et al. The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty.  J Orthop . 2015;12(Suppl 2):S145-51. Published 2015 Nov 28. doi:10.1016/j.jor.2015.10.023https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796661/
31CYP2C19Kaneko, A., Lum, J. K., Yaviong, L., Takahashi, N., Ishizaki, T., Bertilsson, L., et al. (1999). High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.  Pharmacogenetics  9, 581–590.https://www.ncbi.nlm.nih.gov/pubmed/10591538
33CYP2D6Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.  Acad Emerg Med . 2014;21(8):879-85.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150819/
34CYP3A4PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenetics and genomics. 2012. Lamba Jatinder, Hebert Joan M, Schuetz Erin G, Klein Teri E, and Altman Russ B.  22407409https://www.pharmgkb.org/vip/PA166169915
35CYP3A5PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenetics and genomics. 2012. Lamba Jatinder, Hebert Joan M, Schuetz Erin G, Klein Teri E, and Altman Russ B.  22407409https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738061/
37ADRA2AHuang, H.-C., Wu, L. S.-H., Yu, S.-C., Wu, B.-J., Lua, A. C., Lee, S.-M., & Liu, C.-Z. (2018). The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Psychiatry Investigation, 15(3), 306–312. http://doi.org/10.30773/pi.2017.07.24http://doi.org/10.30773/pi.2017.07.24
39CYP1A2Kroon, L. A. (2007). Drug interactions with smoking. American Journal of Health-System Pharmacy,64(18), 1917-1921. doi:10.2146/ajhp060414http://www.ajhp.org/content/64/18/1917?sso-checked=true
38CYP1A2Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2012). PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenetics and Genomics, 22(1), 73–77. http://doi.org/10.1097/FPC.0b013e32834c6efdhttps://www.ncbi.nlm.nih.gov/pubmed/21989077
40CYP2B6Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.  Front Genet . 2013;4:24. Published 2013 Mar 5. doi:10.3389/fgene.2013.00024https://www.ncbi.nlm.nih.gov/pubmed/23467454
42CYP4F2 and VKORC1Dean L. Warfarin Therapy and VKORC1 and CYP Genotype. 2012 Mar 8 [Updated 2018 Jun 11]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK84174/https://www.ncbi.nlm.nih.gov/pubmed/28520347
43CYP4F2 and VKORC1Shendre, A., Brown, T. M., Liu, N., Hill, C. E., Beasley, T. M., Nickerson, D. A., & Limdi, N. A. (2016). Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy, 36(3), 263–272. http://doi.org/10.1002/phar.1717https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803610/
45COMT 2. Lin, C., Fan, J., Lin, H., Chang, C., & Wu, Y. (2018). Catechol-O-methyltransferase ( COMT ) genetic variants are associated with cognitive decline in patients with Parkinsons disease. Parkinsonism & Related Disorders, 50, 48-53. doi:10.1016/j.parkreldis.2018.02.015https://www.ncbi.nlm.nih.gov/pubmed/29439855
46DPYDDel Re M, Di Paolo A, van Schaik RH, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?.  EPMA J . 2010;1(3):495-502.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405332/
47Factor II Factor V LeidenLaberge, A.-M., Psaty, B. M., Hindorff, L. A., & Burke, W. (2009). Use of Factor V Leiden genetic testing in practice and impact on management. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 11(10), 750–756. http://doi.org/10.1097/GIM.0b013e3181b3a697https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132195/
49Grik4Paddock, Silvia & Laje, Gonzalo & Charney, Dennis & Rush, Augustus & F Wilson, Alexander & J M Sorant, Alexa & Lipsky, Robert & R Wisniewski, Stephen & Manji, Husseini & Mcmahon, Francis. (2007). Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort. The American journal of psychiatry. 164. 1181-8. 10.1176/appi.ajp.2007.06111790.http://europepmc.org/abstract/med/17671280
50HLA-A/BDean L. Abacavir Therapy and HLA-B*57:01 Genotype. 2015 Sep 1 [Updated 2018 Apr 18]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK315783/https://www.ncbi.nlm.nih.gov/books/NBK315783/
51HLA-A/BCheng, C.-Y., Su, S.-C., Chen, C.-H., Chen, W.-L., Deng, S.-T., & Chung, W.-H. (2014). HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review. Journal of Immunology Research, 2014, 565320. http://doi.org/10.1155/2014/565320https://www.ncbi.nlm.nih.gov/pubmed/24901010
52HTR2ADong ZQ, Li XR, He L, He G, Yu T, Sun XL. 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients.  Neuropsychiatr Dis Treat . 2016;12:1623-9. Published 2016 Jul 4. doi:10.2147/NDT.S93562https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938133/
53HTR2AStevenson JM, Bishop JR (2013) Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Genotypes. Clin Pharmacol Biopharm 2:109. doi:10.4172/2167-065X.1000109https://www.omicsonline.org/open-access/antidepressant-tolerability-and-potential-clinical-implications-of-serotonin-2a-genotypes-2167-065X.1000109.php?aid=16184
54HTR2CDrago A, Serretti A. 2009. Focus on HTR2C: A Possible Suggestion for Genetic Studies of Complex Disorders. Am J Med Genet Part B 150B:601–637.https://onlinelibrary.wiley.com/doi/10.1002/ajmg.b.30864
55HTR2CWallace, T. J., Zai, C. C., Brandl, E. J., & Müller, D. J. (2011). Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.  Pharmacogenomics and personalized medicine ,  4 , 83-93.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513221/
56INFL3Nakamoto, S., Imazeki, F., Kanda, T., Wu, S., Nakamura, M., Yasui, S., Tawada, A., Mikata, R., Chiba, T., Arai, M., Yokosuka, O., … Shirasawa, H. (2017). Association of  IFNL3  Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.  International journal of medical sciences ,  14 (11), 1088-1093. doi:10.7150/ijms.20171https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666539/
58NAT2PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.Pharmacogenetics and genomics. 2014. McDonagh Ellen M, Boukouvala Sotiria, Aklillu Eleni, Hein David W, Altman Russ B, and Klein Teri E.  24892773https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109976/
60OPRM1Mura, E., Govoni, S., Racchi, M., Carossa, V., Ranzani, G. N., Allegri, M., & van Schaik, R. H. (2013). Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?.  Journal of pain research ,  6 , 331-53. doi:10.2147/JPR.S42040https://www.dovepress.com/consequences-of-the-118agtg-polymorphism-in-the-oprm1-gene-translation-peer-reviewed-article-JPR
61SLCO1B1Birmingham, B.K., Bujac, S.R., Elsby, R. et al. Eur J Clin Pharmacol (2015) 71: 341. https://doi.org/10.1007/s00228-014-1801-zhttps://www.ncbi.nlm.nih.gov/pubmed/25673568
62SLCO1B1 Oshiro, C., Mangravite, L., Klein, T., & Altman, R. (2010). PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenetics and Genomics, 20(3), 211–216. http://doi.org/10.1097/FPC.0b013e328333b99chttps://insights.ovid.com/crossref?an=01213011-201003000-00007
63SLCO1B1Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., … Niemi, M. (2014). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology and Therapeutics, 96(4), 423–428. http://doi.org/10.1038/clpt.2014.125https://www.ncbi.nlm.nih.gov/pubmed/24918167
64TMPTWang, L., Pelleymounter, L., Weinshilboum, R., Johnson, J. A., Hebert, J. M., Altman, R. B., & Klein, T. E. (2010). Very important pharmacogene summary: thiopurine S-methyltransferase.  Pharmacogenetics and genomics ,  20 (6), 401-5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086840/
65UTG1A1PharmGKB summary: very important pharmacogene information for UGT1A1.Pharmacogenetics and genomics. 2014. Barbarino Julia M, Haidar Cyrine E, Klein Teri E, and Altman Russ B.  24492252https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091838/
67ProvidersD. Brixner, E. Biltaji, A. Bress, S. Unni, X. Ye, T. Mamiya, K. Ashcraft & J. Biskupiak (2016) The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy, Journal of Medical Economics, 19:3, 213-228,DOI: 10.3111/13696998.2015.1110160https://www.ncbi.nlm.nih.gov/pubmed/26478982
68ProvidersElliott, L. S., Henderson, J. C., Neradilek, M. B., Moyer, N. A., Ashcraft, K. C., & Thirumaran, R. K. (2017). Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.  PloS one ,  12 (2), e0170905. doi:10.1371/journal.pone.0170905https://www.ncbi.nlm.nih.gov/pubmed/28151991
69HomeKlein, E., & Bourdette, D. (2013). Postmarketing adverse drug reactions: A duty to report?.  Neurology. Clinical practice ,  3 (4), 288-294.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787113/
70HomeElliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK (2017) Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS ONE 12(2): e0170905. doi:10.1371/journal.pone.0170905https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170905

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.